| First Author | Li B | Year | 2021 |
| Journal | J Endocrinol | Volume | 249 |
| Issue | 1 | Pages | 1-18 |
| PubMed ID | 33504680 | Mgi Jnum | J:308158 |
| Mgi Id | MGI:6725279 | Doi | 10.1530/JOE-20-0398 |
| Citation | Li B, et al. (2021) Apelin/APJ relieve diabetic cardiomyopathy by reducing microvascular dysfunction. J Endocrinol 249(1):1-18 |
| abstractText | Microcirculatory injuries had been reported to be involved in diabetic cardiomyopathy, which was mainly related to endothelial cell dysfunction. Apelin, an adipokine that is upregulated in diabetes mellitus, was reported to improve endothelial cell dysfunction and attenuate cardiac insufficiency induced by ischemia and reperfusion. Therefore, it is hypothesized that apelin might be involved in alleviating endothelial cell dysfunction and followed cardiomyopathy in diabetes mellitus. The results showed that apelin improved endothelial cell dysfunction via decreasing apoptosis and expression of adhesion molecules and increasing proliferation, angiogenesis, and expression of E-cadherin, VEGFR 2 and Tie-2 in endothelial cells, which resulted in the attenuation of the capillary permeability in cardiac tissues and following diabetic cardiomyopathy. Meanwhile, the results from endothelial cell-specific APJ knockout mice and cultured endothelial cells confirmed that the effects of apelin on endothelial cells were dependent on APJ and the downstream NFkappaB pathways. In conclusion, apelin might reduce microvascular dysfunction induced by diabetes mellitus via improving endothelial dysfunction dependent on APJ activated NFkappaB pathways. |
